NCT03805698

Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Cedars-Sinai Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to compare outcomes and functionality measures of subjects treated with platelet rich plasma (PRP) after arthroscopic debridement of triangular fibrocartilage complex (TFCC) tears to subjects treated with arthroscopic debridement alone.

Detailed description

Patients with triangular fibrocartilage complex (TFCC) tears will undergo treatment with arthroscopic debridement, as is standard of care, followed by treatment with platelet rich plasma (PRP) (24 subjects) versus no treatment with PRP (24 subjects). Outcome measures will include Modified Mayo Wrist scores (pain scale scores, grip strength, wrist range of motion, functional status) and Patient-rated Wrist Evaluation (PRWE) scores.

Conditions

• Arthroscopic Surgery
• Triangular Fibrocartilage Complex Injury

Interventions

Type	Name	Description
DEVICE	Platelet-rich Plasma (PRP)	The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
OTHER	Standard Arthroscopic Debridement	Standard arthroscopic debridement. No PRP injection.

Timeline

• Start date: 2019-01-03
• Primary completion: 2021-02-06
• Completion: 2021-02-06
• First posted: 2019-01-16
• Last updated: 2022-10-06
• Results posted: 2022-10-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study